BRIEF-Roivant Announces Positive Neptune Study Results For Brepocitinib In NIU

Reuters04-02

April 2 (Reuters) - Roivant Sciences Ltd :

* ROIVANT: POSITIVE NEPTUNE STUDY RESULTS FOR BREPOCITINIB IN NIU

* ROIVANT: AUTHORIZATION FOR UP TO $1.5 BILLION SHARE REPURCHASE PROGRAM, INCLUDING REPURCHASE OF ENTIRE SUMITOMO PHARMA STAKE FOR $648 MILLION

* ROIVANT: PHASE 2 NEPTUNE STUDY SECONDARY EFFICACY ENDPOINTS WERE POSITIVE AND DOSE RESPONSIVE

* ROIVANT: REPURCHASE OF ALL 71.3 MILLION SHARES HELD BY SUMITOMO PHARMA AT PURCHASE PRICE OF $9.10 PER SHARE

* ROIVANT: BREPOCITINIB WAS GENERALLY SAFE AND WELL-TOLERATED IN STUDY

* ROIVANT: PRIOVANT THERAPEUTICS INTENDS TO INITIATE A PHASE 3 PROGRAM IN NIU IN H2 2024

* ROIVANT: ONGOING PHASE 3 STUDY EVALUATING BREPOCITINIB IN DERMATOMYOSITIS EXPECTED TO BE FULLY ENROLLED IN Q3 2024, DATA EXPECTED IN 2025

* ROIVANT: BREPOCITINIB WELL-POSITIONED TO SUPPORT POTENTIAL MULTI-BLOCKBUSTER FRANCHISE IN SPECIALTY AUTOIMMUNITY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424018114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-02 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424018114","market":"us","top_or_hot":-1,"title":"BRIEF-Roivant Announces Positive Neptune Study Results For Brepocitinib In NIU","media":"Reuters","content":"<html><body><p>April 2 (Reuters) - Roivant Sciences Ltd   :</p><p>   * ROIVANT: POSITIVE NEPTUNE STUDY RESULTS FOR BREPOCITINIB IN NIU</p><p>   * ROIVANT: AUTHORIZATION FOR UP TO $1.5 BILLION SHARE REPURCHASE PROGRAM, INCLUDING REPURCHASE OF ENTIRE SUMITOMO PHARMA STAKE FOR $648 MILLION</p><p>   * ROIVANT: PHASE 2 NEPTUNE STUDY SECONDARY EFFICACY ENDPOINTS WERE POSITIVE AND DOSE RESPONSIVE</p><p>   * ROIVANT: REPURCHASE OF ALL 71.3 MILLION SHARES HELD BY SUMITOMO PHARMA AT PURCHASE PRICE OF $9.10 PER SHARE</p><p>   * ROIVANT: BREPOCITINIB WAS GENERALLY SAFE AND WELL-TOLERATED IN STUDY</p><p>   * ROIVANT: PRIOVANT THERAPEUTICS INTENDS TO INITIATE A PHASE 3 PROGRAM IN NIU IN H2 2024</p><p>   * ROIVANT: ONGOING PHASE 3 STUDY EVALUATING BREPOCITINIB IN DERMATOMYOSITIS EXPECTED TO BE FULLY ENROLLED IN Q3 2024, DATA EXPECTED IN 2025</p><p>   * ROIVANT: BREPOCITINIB WELL-POSITIONED TO SUPPORT POTENTIAL MULTI-BLOCKBUSTER FRANCHISE IN SPECIALTY AUTOIMMUNITY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Roivant Announces Positive Neptune Study Results For Brepocitinib In NIU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Roivant Announces Positive Neptune Study Results For Brepocitinib In NIU\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-02 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 2 (Reuters) - Roivant Sciences Ltd   :   * ROIVANT: POSITIVE NEPTUNE STUDY RESULTS FOR BREPOCITINIB IN NIU   * ROIVANT: AUTHORIZATION FOR UP TO $1.5 BILLION SHARE REPURCHASE PROGRAM, INCLUDING ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424018114","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424018114","pubTimestamp":1712055605,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 2  - Roivant Sciences Ltd   :   * ROIVANT: POSITIVE NEPTUNE STUDY RESULTS FOR BREPOCITINIB IN NIU   * ROIVANT: AUTHORIZATION FOR UP TO $1.5 BILLION SHARE REPURCHASE PROGRAM, INCLUDING REPURCHASE OF ENTIRE SUMITOMO PHARMA STAKE FOR $648 MILLION   * ROIVANT: PHASE 2 NEPTUNE STUDY SECONDARY EFFICACY ENDPOINTS WERE POSITIVE AND DOSE RESPONSIVE   * ROIVANT: REPURCHASE OF ALL 71.3 MILLION SHARES HELD BY SUMITOMO PHARMA AT PURCHASE PRICE OF $9.10 PER SHARE   * ROIVANT: BREPOCITINIB WAS GENERALLY SAFE AND WELL-TOLERATED IN STUDY   * ROIVANT: PRIOVANT THERAPEUTICS INTENDS TO INITIATE A PHASE 3 PROGRAM IN NIU IN H2 2024   * ROIVANT: ONGOING PHASE 3 STUDY EVALUATING BREPOCITINIB IN DERMATOMYOSITIS EXPECTED TO BE FULLY ENROLLED IN Q3 2024, DATA EXPECTED IN 2025   * ROIVANT: BREPOCITINIB WELL-POSITIONED TO SUPPORT POTENTIAL MULTI-BLOCKBUSTER FRANCHISE IN SPECIALTY AUTOIMMUNITYSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","SG9999002224.SGD":"Allianz Global High Payout SGD","PFE":"辉瑞","LU0058720904.USD":"联博国际健康护理基金A","NIU":"小牛电动","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4568":"美国抗疫概念","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4139":"生物科技","BK4588":"碎股","BK4550":"红杉资本持仓","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","ROIV":"Roivant Sciences Ltd.","BK4581":"高盛持仓","SG9999001176.USD":"United Global Healthcare Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4592":"伊斯兰概念","BK4534":"瑞士信贷持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4585":"ETF&股票定投概念","SG9999002232.USD":"Allianz Global High Payout USD"},"translate_title":"简报——Roivant在牛宣布Brepocitinib的Neptune研究结果为阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NIU":1,"ROIV":0.9,"PFE":0.9},"content_text":"April 2 (Reuters) - Roivant Sciences Ltd   :   * ROIVANT: POSITIVE NEPTUNE STUDY RESULTS FOR BREPOCITINIB IN NIU   * ROIVANT: AUTHORIZATION FOR UP TO $1.5 BILLION SHARE REPURCHASE PROGRAM, INCLUDING REPURCHASE OF ENTIRE SUMITOMO PHARMA STAKE FOR $648 MILLION   * ROIVANT: PHASE 2 NEPTUNE STUDY SECONDARY EFFICACY ENDPOINTS WERE POSITIVE AND DOSE RESPONSIVE   * ROIVANT: REPURCHASE OF ALL 71.3 MILLION SHARES HELD BY SUMITOMO PHARMA AT PURCHASE PRICE OF $9.10 PER SHARE   * ROIVANT: BREPOCITINIB WAS GENERALLY SAFE AND WELL-TOLERATED IN STUDY   * ROIVANT: PRIOVANT THERAPEUTICS INTENDS TO INITIATE A PHASE 3 PROGRAM IN NIU IN H2 2024   * ROIVANT: ONGOING PHASE 3 STUDY EVALUATING BREPOCITINIB IN DERMATOMYOSITIS EXPECTED TO BE FULLY ENROLLED IN Q3 2024, DATA EXPECTED IN 2025   * ROIVANT: BREPOCITINIB WELL-POSITIONED TO SUPPORT POTENTIAL MULTI-BLOCKBUSTER FRANCHISE IN SPECIALTY AUTOIMMUNITYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424018114"}